Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) will announce its earnings results after the market closes on Thursday, November 7th. Analysts expect Maravai LifeSciences to post earnings of $0.00 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $73.40 million during the quarter, compared to the consensus estimate of $71.64 million. Maravai LifeSciences had a negative net margin of 47.41% and a negative return on equity of 4.78%. The firm’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.06) earnings per share. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Maravai LifeSciences Trading Up 1.0 %
NASDAQ MRVI opened at $7.85 on Wednesday. Maravai LifeSciences has a 12 month low of $4.52 and a 12 month high of $11.56. The company has a current ratio of 10.00, a quick ratio of 9.28 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average of $8.25 and a 200-day moving average of $8.52. The company has a market cap of $1.98 billion, a PE ratio of -7.93 and a beta of 0.02.
Analyst Ratings Changes
View Our Latest Stock Report on MRVI
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Read More
- Five stocks we like better than Maravai LifeSciences
- Learn Technical Analysis Skills to Master the Stock Market
- Palantir Cracks $50, Is There Still Time to Get on Board?
- How Can Investors Benefit From After-Hours Trading
- Insider Buying Signals Upside for These 3 Stocks
- 3 Best Fintech Stocks for a Portfolio Boost
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.